This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer (CIRAB)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2010 by Universitätsmedizin Mannheim.
Recruitment status was:  Recruiting
Heidelberg University
Information provided by:
Universitätsmedizin Mannheim Identifier:
First received: April 18, 2009
Last updated: April 27, 2010
Last verified: April 2010

RATIONALE: Cilengitide may stop the growth of brain metastases by blocking blood flow to the tumor. Radiation therapy uses high energy X-rays to kill tumor cells. Giving cilengitide together with radiation therapy may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of cilengitide when given together with whole-brain radiation therapy in treating patients with brain metastases from lung cancer.

Condition Intervention Phase
Brain and Central Nervous System Tumors Lung Cancer Drug: cilengitide Other: pharmacological study Radiation: radiation therapy Phase 1

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Cilengitide (EMD121974) in Combination With Whole Brain Radiotherapy in Patients With Brain Metastases From Lung Cancer - a Single-center, Open-label Phase I Study

Resource links provided by NLM:

Further study details as provided by Universitätsmedizin Mannheim:

Primary Outcome Measures:
  • Dose-limiting toxicity
  • Maximum-tolerated dose

Secondary Outcome Measures:
  • Overall response rate
  • Overall survival
  • Brain-specific progression-free survival (PFS)
  • Tumor-specific PFS
  • Changes in functional MRI imaging studies at 6 and 12 weeks
  • Evidence of early response by functional MRI on days 1, 4, and 12
  • Changes of neurological and neurocognitive function tests at 6 and 12 weeks
  • Safety and toxicity of the combination of cilengitide and whole-brain radiation therapy
  • Pharmacokinetics of cilengitide

Estimated Enrollment: 21
Study Start Date: December 2008
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Detailed Description:


  • Primary

    • To assess the safety and tolerability of daily cilengitide by determining its dose-limiting toxicity and maximum-tolerated dose when combined with concomitant fractionated whole-brain radiation therapy in patients with brain metastases from lung cancer.
  • Secondary

    • To collect evidence of the best overall response rate, overall survival, brain-specific progression-free survival, and tumor-specific progression-free survival of these patients.
    • To collect evidence of changes in functional MRI imaging studies at 6 and 12 weeks after initiation of therapy.
    • To collect evidence of early response by functional MRI (ASL technique) on days 1, 4, and 12, immediately before and after the administration of cilengitide.
    • To collect evidence of changes in neurological and neurocognitive function tests at 6 and 12 weeks after initiation of therapy.
    • To further evaluate the safety and toxicity of the combination of cilengitide and whole-brain radiation therapy.
    • To further evaluate the pharmacokinetics of cilengitide administered daily.


Patients receive oral cilengitide once daily and undergo whole-brain radiotherapy on the same days. Treatment continues for 2 weeks in the absence of disease progression or unacceptable toxicity.

Patients undergo blood sample collection on days 1, 4, 5, and 12 for pharmacokinetic studies.

After completion of study treatment, patients are followed for 10 weeks.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:


  • Histologically confirmed lung cancer (small cell or non-small cell lung cancer)
  • Patient must be eligible for whole-brain radiotherapy
  • Presence of brain metastasis (single or multiple, synchronous or metachronous) from lung cancer not amenable to surgery or radiosurgery (presence of metastases at any other site is allowed)
  • No leptomeningeal metastasis or known subarachnoid spread of tumor


  • ECOG performance status (PS) 0-1 (ECOG PS 2 allowed if due to the presence of cerebral metastases and not due to a high peripheral-tumor load or other reasons)
  • Life expectancy ≥ 3 months
  • Adequate hematologic function
  • Total bilirubin < 1.5 times upper limit of normal (ULN)
  • AST, ALT, and alkaline phosphatase < 2.5 times ULN
  • Creatinine clearance > 60 mL/min
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 6 months after completion of study treatment
  • No history of acute or chronic renal disease
  • No other malignancies treated within the past 5 years, except adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin
  • No uncontrolled hypertension
  • No history of coagulation disorder associated with bleeding or recurrent thrombotic events
  • No peptic ulcer disease within the past 6 months
  • No congestive heart failure, high risk for uncontrolled arrhythmia, or history of clinically significant coronary heart disease
  • No known alcohol or drug abuse
  • No other significant or acute concomitant disease
  • No dementia or altered mental status


  • See Disease Characteristics
  • Concurrent corticosteroids allowed if the dosing regimen has ben stable ≥ 5 days
  • Concurrent anticonvulsants allowed if the dosing regimen has been stable for the past week
  • More than 30 days since prior participation in another clinical trial
  • No concurrent anticoagulation with vitamin K antagonists, therapeutic-dose anticoagulation with heparin resulting in prolonged PTT, or therapeutic-dose anticoagulation with low molecular weight heparin (low-dose [i.e. prophylactic], low molecular weight heparins allowed)
  • No prior whole-brain radiation or radiosurgery
  • No prior antiangiogenic therapy
  • No other concurrent anticancer therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00884598

University Medical Center, Department of Surgery Recruiting
Mannheim, Germany, D-68167
Contact: Christian Manegold, MD    49-621-383-2199   
Sponsors and Collaborators
Universitätsmedizin Mannheim
Heidelberg University
Principal Investigator: Christian Manegold, MD University Medical Center Mannheim
  More Information

Responsible Party: Prof. Dr. Christian Manegold, University Medical Center Mannheim, University of Heidelberg Identifier: NCT00884598     History of Changes
Other Study ID Numbers: CDR0000636508
Study First Received: April 18, 2009
Last Updated: April 27, 2010

Keywords provided by Universitätsmedizin Mannheim:
adult tumors metastatic to brain
extensive stage small cell lung cancer
stage IV non-small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Nervous System Neoplasms
Central Nervous System Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Nervous System Diseases processed this record on July 19, 2017